PMC:7195088 / 1238-1809 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"19","span":{"begin":89,"end":97},"obj":"Species"},{"id":"20","span":{"begin":270,"end":278},"obj":"Species"},{"id":"21","span":{"begin":562,"end":570},"obj":"Species"},{"id":"22","span":{"begin":103,"end":111},"obj":"Disease"},{"id":"23","span":{"begin":553,"end":561},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:9606"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Tax:9606"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:9606"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"MESH:C000657245"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T9","span":{"begin":103,"end":111},"obj":"Disease"},{"id":"T10","span":{"begin":553,"end":561},"obj":"Disease"}],"attributes":[{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":9,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":9,"end":14},"obj":"Chemical"},{"id":"T2","span":{"begin":15,"end":24},"obj":"Chemical"},{"id":"T3","span":{"begin":29,"end":52},"obj":"Chemical"},{"id":"T4","span":{"begin":47,"end":52},"obj":"Chemical"},{"id":"T5","span":{"begin":386,"end":392},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35472"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_34922"}],"text":"Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T15","span":{"begin":113,"end":385},"obj":"Sentence"},{"id":"T16","span":{"begin":386,"end":571},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients."}